Jessica Mattson
Medical · Escondido, CANPI 1669637807
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (47.7%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Dexcom, Inc. accounts for 68.4% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2023 at $10,316 and has fallen 83.9% since, to $1,660 in 2025. Among medical clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 308 payments — averaging $73.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dexcom, Inc.$15K
- AstraZeneca$998
- Boehringer Ingelheim$954
- Novo Nordisk$904
- Corcept Therapeutics$823
- Bayer$719
- plus $3K from 15 others
What the payments were for
- Speaking & faculty fees$10,73048%
- Travel & lodging$3,10214%
- Food & beverage$8,67439%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dexcom, Inc. | 60 | $15,396 |
| AstraZeneca | 27 | $998 |
| Boehringer Ingelheim | 38 | $954 |
| Novo Nordisk | 31 | $904 |
| Corcept Therapeutics | 17 | $823 |
| Bayer | 36 | $719 |
| Abbott | 33 | $682 |
| Lilly USA, LLC | 23 | $391 |
| UCB, Inc. | 3 | $306 |
| Sanofi-aventis U.S. LLC | 10 | $239 |
| Insulet Corporation | 4 | $203 |
| Tandem Diabetes Care, Inc. | 2 | $176 |
| Amgen(2 entities) | 8 | $176 |
| Madrigal Pharmaceuticals | 1 | $147 |
| Medtronic | 3 | $109 |
| Amarin Pharma, Inc. | 2 | $84 |
| Mannkind Corporation | 4 | $68 |
| Amryt Pharma Holdings Ltd | 2 | $56 |
| Radius Health, Inc. | 2 | $29 |
| Esperion Therapeutics, Inc. | 1 | $28 |
| Recordati_rare_diseases_inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DEXCOM G7 GSS (161)$13,356
- DEXCOM STELO GLUCOSE BIOSENSOR$1,150
- DEXCOM G6 TRANSMITTER$888
- FARXIGA$468
- RYBELSUS$363
- Kerendia$241
- REZDIFFRA$147
- FreeStyle Libre$146
- Omnipod$141
- FreeStyle Libre 2$127
- Bimzelx$125
- Wegovy$122
- t-slim insulin pump$121
How this compares
$22,505 in reported general payments places this provider in the 95th percentile of 2,087 medical providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 131 | $270,480 |
| JardianceEmpagliflozin | 89 | $127,412 |
| MounjaroTirzepatide | 55 | $106,742 |
| RybelsusSemaglutide | 43 | $74,637 |
| TrulicityDulaglutide | 36 | $74,132 |
| FarxigaDapagliflozin Propanediol | 30 | $40,184 |
| JanuviaSitagliptin Phosphate | 19 | $30,894 |
| Tresiba Flextouch U-100Insulin Degludec | 22 | $14,584 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 25 | $13,945 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 11 | $13,540 |
| Novolog FlexpenInsulin Aspart | 27 | $5,470 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 38 | $4,776 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 46 | $4,680 |
| Metformin Hcl ErMetformin Hcl | 71 | $1,851 |
| SynthroidLevothyroxine Sodium | 15 | $1,015 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $904 | $345,117174 claims |
| Lilly USA, LLCMounjaro, Trulicity | $391 | $180,87391 claims |
| Boehringer IngelheimJardiance | $954 | $127,41289 claims |
| AstraZenecaFarxiga | $998 | $40,18430 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,087 medical providers in California.
Other medical in Escondido
- Nalani HunsakerEscondido$39K
- Nicola LowreyOrange$655K
- Justin LoveLoma Linda$553K
- Alison GracomIrvine$467K
- Jeffrey BonnaudLos Angeles$314K
- Ana TorresLaguna Beach$229K
- Heather ParlettRedlands$168K
- David DoriguzziLancaster$166K
- Deirdre MoxleyFullerton$149K
- Linda RankLadera Ranch$105K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.